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Background: Currently, MELD Score listing is state of the art for liver
transplant recipients. Our department could show by our own institutional data
and confirmed by an Eurotransplant cohort that dynamic MELD deterioration
(Delta MELD) during waiting time has a significant impact on postoperative
survival. Aim of this study was to analyze the risk prediction of posttransplant
survival by adding recipient Sodium values to Delta MELD (Delta MELD-Na).
Method: More than 22,000 patients of the UNOS data base were analyzed,
who were transplanted in the US from 2012 to 5/2016.
MELD-Na was calculated according to this formula
MELD – Na ! [0.025 9 MELD 9 (140 ! Na)] + 140 (na ranges from 125
to 140)
Delta MELD-Na was defined as MELD-Na at listing minus MELD-Na at
transplantation: Delta MELD = MELD-Na (ON) ! MELD-Na (TX)
Delta MAX was the highest MELD-Na deterioration between two observa-
tion time points.
Delta LAST was the alteration between forelast and last observation before
transplantation.
Results: 69.7% of patients showed a stable MELD Na during waiting time for
transplantation with a maximum increase of 4 points. In 15.4% of patients an
increase of 5–9 points was observed. Further 14.8% of patients showed an
increase of 10 and more points. Statistical significant factors for posttransplant
survival were MELD Na ON (p = 0.007), MELD Na TX (p = <0.001) and Delta
MELD-Na and Delta MELD-Na MAX (both p = <0.001). Delta MELD-Na LAST
did not show statistical significance (p = 0.35).
Conclusion: A severe deterioration of MELD- Na during waiting time results
in significantly poor posttransplant survival in liver transplantation. Also
temporary deterioration during waiting time showed similar risk.
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Introduction: Donor livers with ≥ 30% macrosteatosis represent a possible
expansion to the donor pool, but are frequently discarded as they are
associated with an increased risk of graft loss. We hypothesized that there are
certain patient phenotypes that would tolerate donor macrosteatosis well, and
are therefore best suited to receive these grafts.
Methods: Using US national registry data from the SRTR between 2005 and
2017, we compared 2,148 recipients of ≥ 30% macrosteatotic grafts to 23,244
recipients of < 30% macrosteatotic grafts. We defined donor steatosis as any
liver with ≥ 30% macrosteatotic on biopsy, and other livers were considered
non-steatotic. We then identified recipient factors that amplified the effect of
donor steatosis on graft loss using interaction analysis. Recipients without these
factors (i.e. without risk factors that amplified the negative effect of steatotic
donor livers) were classified as preferred recipients. We used Kaplan-Meier
analysis to compare outcomes between preferred and non-preferred recipients.
Results: Preferred recipients of steatotic livers were determined to be first-
time recipients with a MELD < 35, without primary biliary cirrhosis or peritonitis,
and not on life support prior to transplant. Preferred recipients had similar graft
survival when using steatotic donor livers, compared to using non-steatotic
livers (3-year graft survival: 80.6% vs. 79.8%, p = 0.7). In contrast, non-
preferred recipients had worse graft survival when using steatotic donor livers,
compared to non-steatotic livers (3-year graft survival: 69.5% vs. 75.1%,
p = 0.005). Similarly, preferred recipients had equivalent patient survival when
using steatotic donor livers (3-year survival 82.6% vs. 83.1%, p = 0.5),
whereas non-preferred recipients had worse patient survival when using
steatotic donor livers (3-year survival 72.8% vs. 77.9%, p = 0.005).
Conclusion: The risks of steatotic donor livers could be minimized by
appropriate recipient matching.
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Introduction: Due to shortage of donor organs, physicians and surgeons are
forced to accept livers from donation after circulatory death (DCD) donors. One
special group of DCD organs are those obtained after euthanasia (DCD type
V). To create more awareness on the possibility of organ donation after
euthanasia, it is important to evaluate the results of transplantation with this
type of graft. The aim of our study was to evaluate the outcome of DCD type V
liver transplantation (LT) in the Netherlands and Belgium.
Methods: All DCD type V LT performed until 2018 in all three Dutch LT centers
and four out of six Belgian LT centers, were included in this study. Grafts that
have been preserved with machine perfusion were excluded. Continuous data
are expressed as median (IQR), categorical data as number (percentage).
Results: Until 2018, 44 DCD type V LT have been performed. Five cases in
which the liverwaspreservedbymachineperfusionwereexcluded.Medianageof
donor and recipient was 51 years (42–58) and 56 years (48–64), respectively. A
neurological disease was the most common underlying disease in donors
requesting euthanasia, followed by psychiatric disorders. Median time between
administration of the euthanatics and cold perfusion was 19 min (14–25). Peak
AST andALT levels in the recipients were 904 U/l (586–2,478) and 709 U/l (448–
1,841) respectively.One-, three- and five-year patient survival was 90%, 83%and
83%, respectively (figure 1). Five patients (13%) requireda retransplantation, due
to PNF (n = 1), HAT (n = 1) or post-transplant cholangiopathy (n = 3), the
majority within the first year after the prior LT.
Conclusion: Liver transplantations with grafts from donors who underwent
euthanasia yield satisfying results during the relatively short follow up period
that is currently available. Comparison of these results with DCD type III LT and
donation after brain death (DBD) LT is currently ongoing.
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